Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00673725
: May 7, 2008
Last Update Posted
: August 25, 2014
Astellas Pharma Europe B.V.
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Europe B.V. )
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Months to 16 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Has given written informed consent (parents or guardian, child if applicable)
Moderate to severe AD
Continuous use of topical corticosteroid or topical calcineurin inhibitor (TCI) as active treatment of AD for more than 4 weeks prior to screening (no change in topical corticosteroid or TCI is allowed between screening and day 1)
In the opinion of the investigator, subject is unlikely to require a significant change to his/her current treatment regimen during the study period
Has infected lesions
The last assessment of any clinical study within 3 months prior to the expected date of entering into the study
Current use of Locobase® REPAIR
Known allergy to Locobase® REPAIR or any of its components
Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the study